Viral Immunology, Vaccines, and Antivirals
A section of Viruses (ISSN 1999-4915).
Section Information
- acquired resistance and evolution
- regulatory/societal/legislation aspects
- immune system stimulation
- limitations of vaccines
- new developments and the future
- natural antivirals and their uses
- viral infections
- differences between antivirals and antibiotics in health care
- antiviral use in children
- immunology/animal models
- adverse effects
Editorial Board
Topical Advisory Panel
Click here to see the Section Topical Advisory Panel of "Viral Immunology, Vaccines, and Antivirals".
Special Issues
Following special issues within this section are currently open for submissions:
- Recent Advances in Anti-HCV, Anti-HBV and Anti-flavivirus Agents (Deadline: 15 November 2024)
- The Role of Dendritic Cells and Macrophages in HIV Infection (Deadline: 15 November 2024)
- Apoptosis and Necroptosis as Host Defense Strategies to Prevent Viral Infection (Deadline: 20 November 2024)
- Viral Infections and Immune Dysregulation 2024 (Deadline: 25 November 2024)
- The Inflammasomes - Key Players in Antiviral Response (Deadline: 30 November 2024)
- Role of Lectins in Viral Infections and Antiviral Intervention (Deadline: 30 November 2024)
- Viral Replication Inhibitors (Deadline: 30 November 2024)
- Emerging and Re-emerging Zoonotic Viruses: Current Challenges in Vaccinology (Deadline: 30 November 2024)
- How to Adjust the Action Steps for Achieving the Global Hepatitis Virus (HBV/HCV/HDV) Elimination Targets? (Deadline: 30 November 2024)
- Chronic Infection by Oncogenic Viruses (Deadline: 30 November 2024)
- Efficacy, Safety, and Immunogenicity of Vaccines against Viruses: From Network Medicine to Clinical Experimentation 2nd Edition (Deadline: 30 November 2024)
- Unraveling the Pathogenesis of Persistent Virus Infection (Deadline: 30 November 2024)
- The Diverse Regulation of Transcription in Endogenous Retroviruses (Deadline: 30 November 2024)
- Viral Sepsis: Pathogenesis, Diagnostics and Therapeutics (Deadline: 15 December 2024)
- Innate Immunity to Virus Infection 2nd Edition (Deadline: 15 December 2024)
- Conquering Antiviral Drug Resistance via Development of Novel Antivirals and New Testing Methods for Drug Resistance: From Bench to Bedside (Deadline: 31 December 2024)
- Chemokines and Chemokine Receptors in Viral Infection 2024 (Deadline: 31 December 2024)
- Viruses and Virus-Like Particles as Nanoplatforms for Vaccines, Diagnostic and Therapeutic Nanomedicine (Deadline: 31 December 2024)
- Viral Resistance (Deadline: 31 December 2024)
- Novel Antiviral Agents: Synthesis, Molecular Modelling Studies and Biological Investigation, 2nd Edition (Deadline: 31 December 2024)
- Epigenetic and Transcriptional Regulation of DNA Virus Infections (Deadline: 31 December 2024)
- Recent Advances in Antiviral Natural Products 2023 (Deadline: 31 December 2024)
- Elimination of Viral Hepatitis: Improving Diagnosis, Treatment and Surveillance, 2nd Edition (Deadline: 31 December 2024)
- Innate and Adaptive Immune Responses to Arbovirus Infections (Deadline: 15 January 2025)
- Virus-Host Protein Interactions (Deadline: 31 January 2025)
- HIV Protease (Deadline: 31 January 2025)
- Antiviral Agents to Influenza Virus 2024 (Deadline: 31 January 2025)
- Interferon Signaling in Viral Pathogenesis (Deadline: 31 January 2025)
- B Cell-Mediated Immunity to Viruses (Deadline: 19 February 2025)
- Mechanisms of Herpesvirus Resistance (Deadline: 20 February 2025)
- Pharmacology of Antiviral Drugs (Deadline: 28 February 2025)
- Virology and Immunology of Gene Therapy (Deadline: 28 February 2025)
- Antiviral Resistance Mutations (Deadline: 28 February 2025)
- Structure-Guided Antiviral Discovery: From Target Validation to Drug Design to Candidate Selection (Deadline: 28 February 2025)
- Swine Viruses: Immunology and Vaccinology (Deadline: 28 February 2025)
- Antibody Cross-Reactivity in Virus Infection (Deadline: 10 March 2025)
- Host Cell-Virus Interaction, 4th Edition (Deadline: 14 March 2025)
- Host-Directed Antiviral Therapy (Deadline: 15 March 2025)
- Broadly Protective Anti-Viral Vaccines 2025 (Deadline: 20 March 2025)
- Universal Influenza Vaccines for Humans and Animals (Deadline: 31 March 2025)
- Virus Infections and Host Metabolism 2025 (Deadline: 31 March 2025)
- Rabies Virus: Treatment and Prevention (Deadline: 31 March 2025)
- Broad-Spectrum Antivirals and Interaction with Viruses: 2nd Edition (Deadline: 31 March 2025)
- The Challenge of HIV Diversity (Deadline: 15 April 2025)
- Lung Immunity to Viral Infections (Deadline: 20 April 2025)
- Advancements in Immunotherapy for Human Papillomavirus (Deadline: 30 April 2025)
- Nanovaccines against Viral Infection (Deadline: 30 April 2025)
- Modeling the Unholy Trinity of Pandemics: Viral Infection, Immunity, and Virus Transmission 2025 (Deadline: 30 April 2025)
- Antiviral Drugs and Biologics Targeting HIV: Drug Resistance to Newer Treatment and Pre-Exposure Prophylaxis (PrEP) Options (Deadline: 30 April 2025)
- Structure-Based Antiviral Drugs and Vaccine Design (Deadline: 30 April 2025)
- Host Defense, Viruses and Cell Death Pathways (Deadline: 30 April 2025)
- Influenza, SARS-CoV-2, RSV and Other Vaccines: Immunogenicity Parameters and Protection, 3rd Edition (Deadline: 30 May 2025)
- RNA Viruses Replication and Innate Immunity (Deadline: 31 May 2025)
- Advances in Small-Molecule Viral Inhibitors (Deadline: 15 July 2025)
- Natural, Semisynthetic, and Synthetic Antiviral Drugs Targeting HIV and SARS-CoV-2 (Deadline: 31 August 2025)
- Roles of Macrophages in Viral Infections 2nd Edition (Deadline: 31 August 2025)
Topical Collection
Following topical collection within this section is currently open for submissions:
